J&J's Remicade poised to dominate paediatric ulcerative colitis market
This article was originally published in Scrip
Executive Summary
Paediatric patients in Canada will become the first to have access to Remicade (infliximab) for treating moderately to severely active ulcerative colitis, following Health Canada’s approval of the drug for this indication. This decision is likely to pave the way for similar indication extensions for children in other markets.